Reiko Cullum

Ms. Reiko Cullum

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
MKMin Cheol Kim
Min Cheol Kim
RCReiko Cullum
Reiko Cullum
AHAli Hebishy
Ali Hebishy
HMHala A. Mohamed
Hala A. Mohamed
AFAhmed Faraag
Ahmed Faraag
WFWilliam Fenical
William Fenical
New antibiotics are desperately needed to overcome the societal challenges being encountered with methicillin-resistant Staphylococcus aureus (MRSA). In this study, a new tetracene derivative, named Mersaquinone (1), and the known Tetracenomycin D (2), Resistoflavin (3) and Resistomycin (4) have been isolated from the organic extract of the marine Streptomyces sp. EG1. The strain was isolated from a sediment sample collected from the North Coast of the Mediterranean Sea of Egypt. The chemical structure of Mersaquinone (1) was assigned based upon data from a diversity of spectroscopic techniques including HRESIMS, IR, 1D and 2D NMR measurements. Mersaquinone (1) showed antibacterial activity against methicillin-resistant Staphylococcus aureus with a minimum inhibitory concentration of 3.36 μg/mL.


1 January 2024 in ISME Communications
Verified
Journal Article
Open access
PDF file
EHElijah R Bring Horvath
Elijah R Bring Horvath
WBWilliam Brazelton
William Brazelton
MKMin Cheol Kim
Min Cheol Kim
RCReiko Cullum
Reiko Cullum
MMMatthew Mulvey
Matthew Mulvey
JWJaclyn Winter
Jaclyn Winter
Great Salt Lake (GSL), located northwest of Salt Lake City, UT, is the largest terminal lake in the USA. While the average salinity of seawater is ~3.3%, the salinity in GSL ranges between 5% and 28%. In addition to being a hypersaline environment, GSL also contains toxic concentrations of heavy metals, such as arsenic, mercury, and lead. The extreme environment of GSL makes it an intriguing subject of study, both for its unique microbiome and its potential to harbor novel natural product–producing bacteria, which could be used as resources for the discovery of biologically active compounds. Though work has been done to survey and catalog bacteria found in GSL, the Lake’s microbiome is largely unexplored, and little to no work has been done to characterize the natural product potential of GSL microbes. Here, we investigate the bacterial diversity of two important regions within GSL, describe the first genomic characterization of Actinomycetota isolated from GSL sediment, including the identification of two new Actinomycetota species, and provide the first survey of the natural product potential of GSL bacteria.

20 June 2023 in Marine Drugs
Verified
Journal Article
Open access
PDF file
MKMin Cheol Kim
Min Cheol Kim
JWJaclyn Winter
Jaclyn Winter
RCReiko Cullum
Reiko Cullum
ASAlexander Smith
Alexander Smith
WFWilliam Fenical
William Fenical
Marinolides A and B, two new 24- and 26-membered bacterial macrolactones, were isolated from the marine-derived actinobacterium AJS-327 and their stereostructures initially assigned by bioinformatic data analysis. Macrolactones typically possess complex stereochemistry, the assignments of which have been one of the most difficult undertakings in natural products chemistry, and in most cases, the use of X-ray diffraction methods and total synthesis have been the major methods of assigning their absolute configurations. More recently, however, it has become apparent that the integration of bioinformatic data is growing in utility to assign absolute configurations. Genome mining and bioinformatic analysis identified the 97 kb mld biosynthetic cluster harboring seven type I polyketide synthases. A detailed bioinformatic investigation of the ketoreductase and enoylreductase domains within the multimodular polyketide synthases, coupled with NMR and X-ray diffraction data, allowed for the absolute configurations of marinolides A and B to be determined. While using bioinformatics to assign the relative and absolute configurations of natural products has high potential, this method must be coupled with full NMR-based analysis to both confirm bioinformatic assignments as well as any additional modifications that occur during biosynthesis.

26 October 2026 in Marine Drugs
Verified
Journal Article
Open access
PDF file
HFHayley Fong
Hayley Fong
EGElkay Dela Pena Galang
Elkay Dela Pena Galang
RCReiko Cullum
Reiko Cullum
WFWilliam Fenical
William Fenical
Anjan DebnathAnjan Debnath
Anjan Debnath
Naegleria fowleri induces fatal human infection known as primary amoebic meningoencephalitis (PAM). Currently, the recommended treatment does not guarantee uniform survival. Thus, there is an urgent need to find an effective and fast-acting treatment for PAM. Our previous study identified anti-N. fowleri activity of marine microbial metabolite mixtures. We recently isolated a pure compound rutamycin B from an amoebicidal metabolite. We sought to determine the activity of rutamycin B and to identify its target in N. fowleri. We determined the dose–response of rutamycin B against N. fowleri and two mammalian cells and measured potency at different time points. We investigated the combined effect of rutamycin B and amphotericin B on both N. fowleri and mammalian cells. For target identification in N. fowleri, we (i) determined the mitochondrial ATP synthase activity of N. fowleri treated with rutamycin B, and (ii) quantified the production of intracellular reactive oxygen species (ROS) in the presence of the compound. Rutamycin B exhibited potency between 0.02 and 0.3 µM against five strains of N. fowleri and had a selectivity index of 200–300. It achieved nanomolar potency on all five strains within four hours, and the combination of rutamycin B with amphotericin B was synergistic without eliciting toxicity on mammalian cells. Significant inhibition of N. fowleri ATP synthase activity and subsequent ROS production suggest that rutamycin B may target F1FO ATP synthase of the pathogen. Our findings identified a potent marine-derived compound and its potential target in N. fowleri and support further pharmacological studies of rutamycin B for the treatment of PAM.

4 December 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
NPNhan T. Pham
Nhan T. Pham
JAJoana Alves
Joana Alves
FSFiona A. Sargison
Fiona A. Sargison
RCReiko Cullum
Reiko Cullum
JWJan Wildenhain
Jan Wildenhain
Manfred AuerManfred Auer
Manfred Auer
Antimicrobial resistance has emerged as an urgent global public health threat, and development of novel therapeutics for treating infections caused by multi-drug resistant bacteria is urgent. Staphylococcus aureus is a major human and animal pathogen, responsible for high levels of morbidity and mortality worldwide. The intracellular survival of S. aureus in macrophages contributes to immune evasion, dissemination, and resilience to antibiotic treatment. Here, we present a confocal fluorescence imaging assay for monitoring macrophage infection by GFP-tagged Staphylococcus aureus as a front-line tool to identify antibiotic leads. The assay was employed in combination with nanoscaled chemical analyses to facilitate the discovery of a novel, active rifamycin analogue. Our findings indicate a promising new approach to the identification of anti-microbial compounds with macrophage intracellular activity. The novel antibiotic identified here may represent a useful addition to our armoury in tackling the silent pandemic of antimicrobial resistance.